---
title: "研究警報：CFRA 將梯瓦製藥的股票評級從持有上調至買入"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/284832437.md"
description: "CFRA 已將梯瓦製藥的評級從持有上調至買入，將目標價格從 36 美元提高至 42 美元。分析師將 2026 年的每股收益預期下調至 2.11 美元，原因是 Emalex 收購的影響，但維持 2027 年的每股收益預期為 3.09 美元。梯瓦第一季度的業績超出預期，主要得益於創新產品的強勁增長。預計在第三季度完成的 7 億美元 Emalex 收購被視為一項戰略舉措，旨在通過新治療方案增強梯瓦的神經科學產品線，以應對抽動症"
datetime: "2026-04-30T20:30:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284832437.md)
  - [en](https://longbridge.com/en/news/284832437.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284832437.md)
---

# 研究警報：CFRA 將梯瓦製藥的股票評級從持有上調至買入

04:30 PM EDT, 04/30/2026 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We raise our target price to $42 from $36, 13.6x our 2027 EPS forecast of $3.09, aboveTEVA's historical forward P/E average, justified in our view, by its improving growth prospects. We lower our 2026 EPS estimate to $2.11 from $2.77 to adjust for the Emalex acquisition impact. We keep our 2027 EPS estimate at $3.09. Teva reported a solid Q1, beating expectations, driven by the continued strong performance of its innovative growth engines (AUSTEDO, AJOVY, and UZEDY) which collectively grew 41% and are successfully offsetting the anticipated revenue decline from the loss of exclusivity for the generic REVLIMID. The newly announced $700M Emalex acquisition, expected to close in Q3, is a significant strategic move, and a major positive, in our view. The deal will bring the NDA-ready, first-in-class lead asset Ecopipam to treat Tourette syndrome, which has a significant unmet need, into Teva's neuroscience pipeline. We think the acquisition can accelerate TEVA's shift toward innovative, high-margin products.

MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.

### 相關股票

- [TEVA.US](https://longbridge.com/zh-HK/quote/TEVA.US.md)

## 相關資訊與研究

- [梯瓦製藥（TEVA.US）盤中大漲近 9% 新增長戰略引關注](https://longbridge.com/zh-HK/news/284585517.md)
- [梯瓦製藥因其強勁的執行力、收購 Emalex 公司以及神經學產品線潛力的增長，被上調至 45 美元的目標價](https://longbridge.com/zh-HK/news/284633339.md)
- [戴蒙稱利率恐大幅攀升 通膨或將高到人們不願持有長天期證券](https://longbridge.com/zh-HK/news/287231453.md)
- [中創智領參股公司洛陽軸承申請上市，獲深交所上市審核委通過](https://longbridge.com/zh-HK/news/286982676.md)
- [大行報告丨花旗上調中芯國際評級至買入](https://longbridge.com/zh-HK/news/286705955.md)